GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cryosite Ltd (ASX:CTE) » Definitions » Capex-to-Operating-Cash-Flow

Cryosite (ASX:CTE) Capex-to-Operating-Cash-Flow : 0.16 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Cryosite Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Cryosite's Capital Expenditure for the six months ended in Dec. 2023 was A$-0.20 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was A$1.22 Mil.

Hence, Cryosite's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.16.


Cryosite Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Cryosite's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryosite Capex-to-Operating-Cash-Flow Chart

Cryosite Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.71 0.81 0.34 0.21

Cryosite Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.60 0.22 0.21 0.16

Competitive Comparison of Cryosite's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Cryosite's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cryosite's Capex-to-Operating-Cash-Flow falls into.



Cryosite Capex-to-Operating-Cash-Flow Calculation

Cryosite's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.301) / 1.408
=0.21

Cryosite's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.196) / 1.219
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryosite  (ASX:CTE) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Cryosite Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cryosite's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryosite (ASX:CTE) Business Description

Traded in Other Exchanges
N/A
Address
13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd is engaged in the provision of supply chain logistics, management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.

Cryosite (ASX:CTE) Headlines

No Headlines